(Q33157844)

English

Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

enzyme replacement therapy

0 references

mucopolysaccharidosis II

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Torayuki Okuyama

1

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Akemi Tanaka

2

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Yasuyuki Suzuki

3

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Hiroyuki Ida

4

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Toju Tanaka

5

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Gerald F Cox

6

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Yoshikatsu Eto

7

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Tadao Orii

8

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Molecular Genetics and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

99

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

18-25

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Molecular analysis in 23 Hunter disease families

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated Korean Hunter syndrome patients: identification of 13 novel mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Molecular and phenotypic variation in patients with severe Hunter syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Mucopolysaccharidosis type II (Hunter disease): 13 gene mutations in 52 Japanese patients and carrier detection in four families

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Natural history of extensive Mongolian spots in mucopolysaccharidosis type II (Hunter syndrome): a survey among 52 Japanese patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

The frequency of lysosomal storage diseases in The Netherlands.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Prevalence of lysosomal storage diseases in Portugal

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Cumulative incidence rates of the mucopolysaccharidoses in Germany

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Long-term follow-up following bone marrow transplantation for Hunter disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Lysosomal Storage Diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Standardization of Spirometry, 1994 Update. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Night-to-night variation of the oxygen desaturation index in sleep apnoea syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Reference equations for the six-minute walk in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Reliability and limitations of echocardiographic measurement of left ventricular mass for risk stratification and follow-up in single patients: the RES trial. Working Group on Heart and Hypertension of the Italian Society of Hypertension. Reliabilit

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.08.006

7 January 2021

Identifiers

10.1016/J.YMGME.2009.08.006

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33157844&oldid=1983349015"